• 20 results in Exploration of Targeted Anti-tumor Therapy
    Sort by
    Latest
    Open Access
    Meeting Abstracts
    Selected meeting abstracts of 2nd International Conference on Contemporary Oncology
    Chouaib Salem
    Published: June 28, 2024 Explor Target Antitumor Ther. 2024;5:789–799
    DOI: https://doi.org/10.37349/etat.2024.00247
    View:453
    Download:17
    Times Cited: 0
    Open Access
    Case Report
    Response to trametinib, hydroxychloroquine, and bevacizumab in a young woman with NRAS-mutated metastatic intrahepatic cholangiocarcinoma: a case report
    Systemic chemotherapy is the main treatment option for patients with advanced intrahepatic cholangiocarcinoma (iCCA), however, its efficacy is limited. Herein, we report a young patient with NRAS-mu [...] Read more.
    Aram A. Musaelyan ... Sergey V. Orlov
    Published: June 28, 2024 Explor Target Antitumor Ther. 2024;5:780–788
    DOI: https://doi.org/10.37349/etat.2024.00246
    View:530
    Download:15
    Times Cited: 0
    Open Access
    Original Article
    Imaging of supratentorial ependymomas with radio-pathological correlation
    Aim: Supratentorial ependymoma (STE) is a rare tumor with distinct genetic alterations, whose imaging features have been scarcely studied. This study aims to review the computed tomography (CT) a [...] Read more.
    Arpita Sahu ... Epari Sridhar
    Published: June 27, 2024 Explor Target Antitumor Ther. 2024;5:766–779
    DOI: https://doi.org/10.37349/etat.2024.00245
    This article belongs to the special issue Theranostic Frontiers in Neuro-Oncology
    View:531
    Download:9
    Times Cited: 0
    Open Access
    Review
    Current status of molecular diagnostics for lung cancer
    The management of lung cancer (LC) requires the analysis of a diverse spectrum of molecular targets, including kinase activating mutations in EGFR, ERBB2 (HER2), BRAF and MET oncogenes, [...] Read more.
    Evgeny N. Imyanitov ... Sergey V. Orlov
    Published: June 27, 2024 Explor Target Antitumor Ther. 2024;5:742–765
    DOI: https://doi.org/10.37349/etat.2024.00244
    This article belongs to the special issue Integrated Approaches for Non-Small-Cell Lung Cancer
    View:948
    Download:28
    Times Cited: 0
    Open Access
    Review
    Antibody-drug conjugates combinations in cancer treatment
    Antibody-drug conjugates (ADCs) have emerged as a promising class of anticancer agents. Currently, the Food and Drug Administration has granted approval to 12 compounds, with 2 later undergoing with [...] Read more.
    Giulia Pretelli ... Anastasios Stathis
    Published: June 27, 2024 Explor Target Antitumor Ther. 2024;5:714–741
    DOI: https://doi.org/10.37349/etat.2024.00243
    This article belongs to the special issue Antibody-Drug Conjugates
    View:600
    Download:19
    Times Cited: 0
    Open Access
    Review
    Promising immunotherapeutic approaches for primary effusion lymphoma
    Primary effusion lymphoma (PEL) is a large B-cell neoplasm usually presenting as a serious effusion in body cavities without detectable tumor masses. It is an AIDS-related non-Hodgkin’s lymphoma ( [...] Read more.
    Jutatip Panaampon, Seiji Okada
    Published: June 26, 2024 Explor Target Antitumor Ther. 2024;5:699–713
    DOI: https://doi.org/10.37349/etat.2024.00242
    This article belongs to the special issue Novel Strategies and Targets for Immunotherapy of Cancer
    View:677
    Download:18
    Times Cited: 0
    Open Access
    Review
    DNA damage targeted therapy for advanced breast cancer
    Breast cancer (BC) is the most prevalent malignancy affecting women worldwide, including Portugal. While the majority of BC cases are sporadic, hereditary forms account for 5-10% of cases. The most  [...] Read more.
    Vanessa Patel ... Luís Costa
    Published: June 25, 2024 Explor Target Antitumor Ther. 2024;5:678–698
    DOI: https://doi.org/10.37349/etat.2024.00241
    View:684
    Download:18
    Times Cited: 0
    Open Access
    Review
    Landscape of targeted therapies for advanced urothelial carcinoma
    Bladder cancer (BC) is the tenth most common malignancy globally. Urothelial carcinoma (UC) is a major type of BC, and advanced UC (aUC) is associated with poor clinical outcomes and limited surviva [...] Read more.
    Shihao Shang ... Zheng Zhu
    Published: June 21, 2024 Explor Target Antitumor Ther. 2024;5:641–677
    DOI: https://doi.org/10.37349/etat.2024.00240
    This article belongs to the special issue Emerging Molecular Targets and Therapies of Genitourinary Tumors
    View:733
    Download:29
    Times Cited: 0
    Open Access
    Review
    Clinical relevance of circulating tumor DNA in ovarian cancer: current issues and future opportunities
    Ovarian cancer (OC) is the most lethal gynecologic malignancy worldwide. Due to the lack of effective screening and early detection strategies, many patients with OC are diagnosed with advanced dise [...] Read more.
    Elena Trevisi ... Ilaria Colombo
    Published: June 19, 2024 Explor Target Antitumor Ther. 2024;5:627–640
    DOI: https://doi.org/10.37349/etat.2024.00239
    This article belongs to the special issue The Implementation of Liquid Biopsy in Clinical Practice for Different Solid Tumor
    View:659
    Download:21
    Times Cited: 0
    Open Access
    Original Article
    Evaluation of antitumor potential of an anti-glypican-1 monoclonal antibody in preclinical lung cancer models reveals a distinct mechanism of action
    Aim: The main objective of this study was to investigate the antitumor effect of a mouse anti-human glypican-1 (GPC1) monoclonal antibody (mAb) on non-small cell lung carcinoma (NSCLC) and associ [...] Read more.
    Minghua Li ... Qingyu Zhou
    Published: June 17, 2024 Explor Target Antitumor Ther. 2024;5:600–626
    DOI: https://doi.org/10.37349/etat.2024.00238
    This article belongs to the special issue Molecular Diagnosis and Personalized Therapy of Cancer
    View:569
    Download:13
    Times Cited: 0